#Australia #Perth #Remplir #Orthocell #Nerve Wrap

Orthocell's Remarkable October Sales Performance for Remplir™

Orthocell Limited, the Australian company behind the innovative Remplir™ collagen nerve wrap, has announced a remarkable increase in sales for the product in the U.S. market. This October marked the highest sales month since the product's launch, signifying the success of Orthocell's strategy and the growing acceptance of Remplir™ among U.S. surgeons.

Key Sales Figures

In October 2026, Orthocell reported the sale of 92 units of Remplir™, generating impressive revenue of AU$279,000. This figure represents a notable 84% increase compared to the average monthly sales of 50 units recorded during the first quarter of FY27. Such substantial growth showcases the growing momentum behind Remplir™ in key international markets.

Factors Contributing to Success

The upward trend in sales can be attributed to several compelling factors:
1. Surgeon Adoption: A growing number of surgeons are becoming familiar with Remplir™, leading to increased utilization in nerve repair surgeries. This heightened familiarity is crucial for the successful integration of new medical technologies into existing practices.
2. Repeat Utilization: As surgeons gain confidence in their use of the device, repeat purchases are on the rise. This has resulted in a solid foundation for ongoing demand and revenue generation.
3. Expanded Distribution: Orthocell has enhanced its network of actively selling distributor representatives, improving market access and ensuring that the product reaches more hospitals and surgical centers.
4. Broader Hospital Access: The company's efforts to secure broader access in key U.S. markets have paid off, as more healthcare institutions recognize the benefits of using Remplir™ in peripheral nerve repair.

Future Outlook

Orthocell's CEO, Paul Anderson, expressed excitement over October's achievements, stating, "This represents an important milestone in Orthocell's U.S. commercialization, with the groundwork laid over the past 12 months now translating into tangible revenue." Anderson emphasized that while the process of establishing a new medical technology in a large market requires time and sustained effort, the company remains committed to accelerating the adoption of Remplir™, expanding hospital access, and increasing product utilization among surgeons.

Moreover, the October sales figures signify not only immediate financial success but also a hopeful outlook for long-term growth. With regulatory approvals secured in seven international jurisdictions, Orthocell is well-positioned to build upon this positive momentum. Their commercial strategy focuses on reinforcing surgical adoption and strengthening active distributor networks to support ongoing utilization of Remplir™ across approved markets.

The Board's Perspective

John Van Der Wielen, Orthocell's Chairman, is optimistic about the future, stating that the Board is encouraged by the positive sales result. He highlighted the company's ongoing investment in commercial infrastructure and manufacturing capabilities to meet increasing demand. Van Der Wielen expressed confidence in Remplir™'s substantial market potential in the U.S. and reiterated the company's strategy to convert growing market acceptance into sustained success.

In conclusion, Orthocell's latest sales figures for Remplir™ exhibit not only company performance but also hint at a larger trend in nerve repair technologies. As surgeons and healthcare providers increasingly recognize the advantages of using innovative solutions like Remplir™, Orthocell stands to benefit from this shift, paving the way for further growth and advancement in the medical device industry.